FDA mulls licensing seven wellness peptides amid safety questions and RFK Jr backing

The FDA's Pharmacy Compounding Advisory Committee is weighing whether seven peptide compounds marketed for sleep, weight loss, wound healing and anti‑aging can be legally compounded by licensed pharmacies with prescriptions, despite limited human trials and concerns over quality and safety. Demand has surged via wellness clinics and influencers, including RFK Jr, fueling debate about oversight. The committee's nonbinding guidance will shape the FDA's final decision, while questions over potential conflicts of interest among panel members remain unresolved.